Long-term use of lurasidone in patients with bipolar disorder: safety and effectiveness over 2 years of treatment.

ABSTRACT:

Background

Bipolar disorder is a chronic illness with a 2-year recurrence rate of approximately 50% among individuals receiving treatment in the community. The aim of this 18-month, open-label, continuation study was to evaluate the long-term safety and effectiveness of lurasidone in patients who initially presented with a major depressive episode associated with bipolar disorder, and who had completed at least 6 months of initial treatment with lurasidone.

Methods

Patients with bipolar I depression were enrolled in one of three 6-week, double-blind, placebo-controlled trials (monotherapy with lurasidone, 1 study; adjunctive therapy with lurasidone; and lithium or valproate, 2 studies). Study completers were eligible for a 6-month, open-label extension study of lurasidone ut

SUBMITTER: Pikalov A 

PROVIDER: S-EPMC5332323 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature